Specialty and rare diseases have undefined patient populations, with individuals who are undiagnosed or misdiagnosed, healthcare providers who are unaware of disease states and their manifestations, as well as treatment journeys that are not well-understood. Until now, no one in the industry had the necessary technology, capabilities and domain expertise to help pharmaceutical and biopharmaceutical companies define, recruit and engage patients who could benefit from new therapies and modalities of care. Enter IPM.ai.
Through this solution overview, you'll learn firsthand how IPM.ai, an Insights as a Service (IaaS) provider, empowers the world’s leading life sciences companies to better understand and improve the lives of patients through the development and commercialization of precision medicine for specialty and rare diseases. IPM’s system of insight streamlines market assessment, patient finding, treatment journey mapping, healthcare provider discovery, key opinion leader identification and brand activation by utilizing granular-level longitudinal analytics, artificial intelligence and machine learning in conjunction with a real world evidence, social determinants of health and outcomes research data universe of over 300 million de-identified patients.